Q-omics provides the consensus-scored TMEM30A-DT profile across patient tissues and cancer cell-line models. TMEM30A-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TMEM30A-DT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TMEM30A-DT RNA expression shows 19,211 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where TMEM30A-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM30A-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM30A-DT survival associations across molecular data types. TMEM30A-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM30A-DT RNA expression–survival associations across cancer types. High TMEM30A-DT expression shows unfavorable associations in KICH, KIRP and ACC, but favorable associations in UCS, BRCA and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for TMEM30A-DT RNA expression.
This table summarizes TMEM30A-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM30A-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM30A-DT shows lower tumor expression in KIRC, THCA, KICH, BRCA and LUSC and higher tumor expression in LIHC. The KIRC box plot shows higher TMEM30A-DT RNA expression in normal versus tumor tissue (log2 FC = −0.400, t-test p < 0.001).
This table shows molecular features associated with TMEM30A-DT in patient tissues and cancer cell lines. In patient samples, TMEM30A-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
